To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Completed · Phase 1

Conditions studied: Renal Impairment

In brief

The primary purpose is to assess the effect of renal impairment on the PK of tavapadon following administration of a single oral dose in participants with severe renal impairment relative to age, body weight, and sex-matched participants with normal renal function.

Key facts

Study ID

NCT05404542

Run by

Cerevel Therapeutics, LLC

People needed

14

Starts

2022-05-10

Expected to finish

2023-08-14

Last updated by the study team

2024-04-02

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

Where it is running

• Jacksonville, Florida — Jacksonville, Florida, United States
• Miami, Florida — Miami, Florida, United States
• Tampa, Florida — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.